The RestoreX™, patented and designed by Dr. Landon TROST, uses a unique dual traction force to correct penile curvature and regain length, with clinically proven results.
Dr. Landon TROST
RestoreX™ was invented by Dr. Landon TROST, an American Urologist specializing in Peyronie's disease and author of multiple studies and clinical recommendations concerning this pathology.
Made in the USA
The RestoreX™ has been patented to validate the exclusivity of the dual traction force technology.
It is manufactured in the United States by PathRight Medical, a company based in Orem, Utah.
Unique and Effective Medical Traction
Thanks to the system of fixing the rod on a duckbill-shaped support distributing the pressure over a very large surface, the axial force is between 3.5 and 4 kg and that on the counter-curvature between 4.5 and 5 kg.
This powerful dual traction is the main reason why RestoreX™ is so effective, unmatched by other traction therapy devices.
RestoreX™ is effective in correcting penile curvature but also in treating hourglass penises.
RestoreX™ is, apart from surgery, the only treatment that has shown tangible results regarding the recovery of penis length 1b, 2b .
The RestoreX™ benefits from the CE marking, which classifies it as a genuine Medical Device.
MJ Ziegelmann & al. - 2019: Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial
110 patients, mean age 58 years, Lapeyronie's anteriority: 49 months, mean curvature 59.3 degrees.
4 groups: 1 control group (n=27) and 3 others with 30-minute sessions → 1 (n=28) or 2 (n=28) or 3 (n=27)
times/day; 15 min protocol in axial traction and 15 min in counter-curvature.
A. Results at 3 months, average use of 47 minutes/day
- Reduction in curvature of 17.2° or 28% for 77% of patients who responded to treatment (control group)
= +1.3°).
- Recovery of penis length: +1.6 cm or +11% for 94% of patients who responded to treatment
(control group = +0.3cm).
- Improvement in erectile function according to IIEF score of 4.3 (control group = 0.7).
- 47% of patients were unable to have sexual intercourse: after 12 weeks, 80% of them reported having penetrative sexual intercourse.
- No adverse effects were observed.
- 100% of patients who had previously tried another traction therapy device reported preferring the RestoreX™.
B. 2 additional phases of the clinical study at 6 (n=64) and 9 (n=63) months of follow-up, daily use
average of 31 min/day
- 63% of patients reported improvements in curvature and length (+0.5cm).
- The International Index of Erectile Function (IIEF) questionnaire score was also increased.
- 84% of patients continued to use RestoreX™ after 9 months.
